drug
lubiprostone
Marketedupdated 5mo agoby Mallinckrodt LLC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying lubiprostone
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 23, 2027
112 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Oct 25, 2027formulationUS 80263931.1y
- Oct 25, 2027formulationUS 80263931.1y
- Jan 23, 2027formulationUS 8338639112d
- Jan 23, 2027formulationUS 8338639112d
- Jan 23, 2027formulationUS 8779187112d
- Jan 23, 2027formulationUS 8779187112d
News(1)
- Takeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appealTakeda has updated its financial results to reflect costs it could incur after losing an antitrust lawsuit concerning its laxative drug Amitiza. In May, the US District Court in Massachusetts ruled…endpoints · 3mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that